title: TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: an open label study.
abstract: We recently reported an association between TAAR6 (trace amine associated receptor 6 gene) variations and schizophrenia (SZ). We now report an association of a set of TAAR6 variations and clinical presentation and outcome in a sample of 240 SZ Korean patients. Patients were selected by a Structured Clinical Interview, DSM-IV Axis I disorders - Clinical Version (SCID-CV). Other psychiatric or neurologic disorders, as well as medical diseases, were exclusion criteria. To assess symptom severity, patients were administered the CGI scale and the PANSS at baseline and at the moment of discharge, 1 month later on average. TAAR6 variations rs6903874, rs7452939, rs8192625 and rs4305745 were investigated; rs6903874, rs7452939 and rs8192625 entered the statistical investigation after LD analysis. Rs8192625 G/G homozygosis was found to be significantly associated both with a worse clinical presentation at PANSS total and positive scores and with a shorter period of illness before hospitalization. No haplotype significant findings were found. The present study stands for a role of the TAAR6 in the clinical presentation of SZ. Moreover, our results show that this genetic effect may be counteracted by a correct treatment. Haplotype analysis was not informative in our sample, probably also because of the incomplete SNPs' coverage of the gene we performed. Further studies in this direction are warranted.
authors.affiliation: Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea. pae@catholic.ac.kr
authors.forename: Chi-Un
authors.initials: CU
authors.lastname: Pae
authors.forename: Antonio
authors.initials: A
authors.lastname: Drago
authors.forename: Jung-Jin
authors.initials: JJ
authors.lastname: Kim
authors.forename: Ashwin A
authors.initials: AA
authors.lastname: Patkar
authors.forename: Tae-Youn
authors.initials: TY
authors.lastname: Jun
authors.forename: Chul
authors.initials: C
authors.lastname: Lee
authors.forename: Laura
authors.initials: L
authors.lastname: Mandelli
authors.forename: Diana
authors.initials: D
authors.lastname: De Ronchi
authors.forename: In-Ho
authors.initials: IH
authors.lastname: Paik
authors.forename: Alessandro
authors.initials: A
authors.lastname: Serretti
mesh_terms: D000328:Adult; D000483:Alleles; D014150:Antipsychotic Agents / Q000627:therapeutic use; D018797:Cell Cycle Proteins / Q000235:genetics*; D005260:Female; D006239:Haplotypes; D006720:Homozygote; D006801:Humans; D007723:Korea; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D043562:Receptors, G-Protein-Coupled; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome; D055815:Young Adult; D000095383:Trace Amine-Associated Receptors
chemical_list: D014150:Antipsychotic Agents; D018797:Cell Cycle Proteins; D009687:Nuclear Proteins; D043562:Receptors, G-Protein-Coupled; C493988:TAAR6 protein, human; D000095383:Trace Amine-Associated Receptors